Leerink Swann Upgrades Vivus (VVUS) to Outperform; Becoming A More Attractive Asset For Big Pharma After Qnexa Approval
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Price: $0.47 --0%
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
3 Buy, 6 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Leerink Swann upgraded Vivus (NASDAQ: VVUS) to Outperform.
Analyst, Joshua Schimmer, said, "Yesterday, the FDA advisory panel voted 20-2 for approval of Qnexa. Although some panel members expressed concerns about the need for a CV outcomes trial, it did not deter them from voting in favor of approval. We expect Qnexa to generate significant sales upon 3Q12 launch and VVUS could become an attractive asset for a company seeking to leverage its primary care salesforce. We upgrade to Outperform and raise our valuation to high $20's."
For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $10.55 yesterday.
Analyst, Joshua Schimmer, said, "Yesterday, the FDA advisory panel voted 20-2 for approval of Qnexa. Although some panel members expressed concerns about the need for a CV outcomes trial, it did not deter them from voting in favor of approval. We expect Qnexa to generate significant sales upon 3Q12 launch and VVUS could become an attractive asset for a company seeking to leverage its primary care salesforce. We upgrade to Outperform and raise our valuation to high $20's."
For an analyst ratings summary and ratings history on Vivus click here. For more ratings news on Vivus click here.
Shares of Vivus closed at $10.55 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
- Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
- Jefferies Downgrades IDP Education (IEL:AU) (IDPUF) to Hold
Create E-mail Alert Related Categories
Analyst EPS Change, Rumors, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
